Maze Therapeutics (MAZE) Accumulated Expenses (2024 - 2026)

Maze Therapeutics has disclosed Accumulated Expenses across 3 years of filings, most recently posting $5.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.4 million, down 53.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (down 53.07% YoY), and the FY2025 annual result was $16.0 million, up 13.23% from the prior year.
• Accumulated Expenses came in at $5.4 million for Q1 2026 at Maze Therapeutics, down from $16.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.0 million in Q4 2025 to a low of $5.4 million in Q1 2026.
• The 3-year median for Accumulated Expenses is $12.8 million (2024), against an average of $11.2 million.
• Across the five-year window, Accumulated Expenses advanced 13.23% in 2025 and plunged 53.07% in 2026, its largest moves.
• Maze Therapeutics' Accumulated Expenses stood at $14.1 million in 2024, then gained by 13.23% to $16.0 million in 2025, then tumbled by 66.09% to $5.4 million in 2026.
• The last three Accumulated Expenses figures came in at $5.4 million (Q1 2026), $16.0 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.